Indo US Bio-Tech Q1 FY27: revenue up 7% YoY but PAT falls 35% as margins compress

Indo US Bio-Tech's standalone Q1 FY27 (quarter ended June 30, 2026) revenue rose 7.2% YoY to ₹32.99 Cr from ₹30.77 Cr, but net profit fell 35.4% YoY to ₹3.04 Cr from ₹4.70 Cr, with EPS at ₹1.51 against ₹2.35 a year ago. Sequentially the print looks strong — PAT is up 54.1% QoQ and revenue 26.8% QoQ over a soft Q4 FY26 (₹26.02 Cr revenue, ₹1.97 Cr PAT) — but for a seed cultivation/processing business with a pronounced kharif-season skew, that QoQ jump is a seasonality artifact; the YoY comparison is the one that matters, and on that basis profitability is weaker than a year ago even as revenue grew.

The compression sits in operating profitability: OPM fell to roughly 12.0% from 17.8% a year ago, and is also down slightly from 12.4% in Q4 FY26, with production expenses and finance costs both higher in proportion to revenue. Net margin narrowed to 9.2% from 15.3% YoY, even as it improved from 7.6% in the immediately preceding quarter. There were no exceptional or prior-period items in either the current or year-ago quarter, so the YoY decline is a clean operating-basis comparison, not a one-off distortion.

The stock went into the print at ₹80.05, down 11.2% over the past month of trading.

Single reportable segment (Seed Cultivation, Processing & Trading) — no investor complaints pending during the quarter

The company has no formal analyst coverage or published guidance on record, and a web search turned up no Q1 FY27 preview or consensus estimate for this stock, so vs-street and vs-guidance both read unknown here; a management press release accompanying the filing was also not available for this extraction. Separately, the quarter carried two governance changes unrelated to the print: Bhagat & Associates was appointed statutory auditor in July 2026 (replacing Gautam N Associates, which resigned in June) — it is this newly appointed firm that reviewed the current result — and the board reconstituted committees following a director resignation on July 3, 2026.